Ardent Health (ARDT) Projected to Post Earnings on Wednesday

Ardent Health (NYSE:ARDT) will likely be posting its Q4 2025 results after the market closes on Wednesday, March 4th. Analysts expect the company to announce earnings of $0.35 per share and revenue of $1.6312 billion for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 10:00 AM ET.

Ardent Health Price Performance

ARDT stock opened at $9.38 on Monday. The firm has a 50 day moving average of $8.96 and a 200-day moving average of $11.09. The firm has a market capitalization of $1.34 billion, a P/E ratio of 6.47, a price-to-earnings-growth ratio of 5.17 and a beta of 0.45. Ardent Health has a 12 month low of $8.07 and a 12 month high of $15.55. The company has a current ratio of 2.08, a quick ratio of 1.95 and a debt-to-equity ratio of 0.67.

Key Ardent Health News

Here are the key news stories impacting Ardent Health this week:

• Positive Sentiment: Ardent announced a partnership with hellocare.ai to deploy enterprise AI‑assisted virtual physician, nursing, patient safety and intelligent care delivery — a commercial/operational move that could improve care efficiency and reduce costs over time. Ardent Health and hellocare.ai Partner
• Negative Sentiment: Multiple firms (Hagens Berman, BFA Law and others) highlight allegations that Ardent used a rigid 180‑day cliff to reserve uncollectible accounts and disclosed an approximate $97M accounting impact — the substantive allegations are the primary catalyst for investor concern and the earlier ~33% share decline. Hagens Berman: $97M accounting shock BFA Law investor alert
• Negative Sentiment: A flood of plaintiff‑side notices from Rosen, Faruqi & Faruqi, The Gross Law Firm, Holzer & Holzer, ClaimsFiler and others are urging shareholders to contact counsel and apply for lead‑plaintiff roles ahead of March 9 (and in one notice April 21) deadlines — these filings increase legal costs, distraction for management, and the odds of class‑action recovery pressure on future earnings. Examples: Rosen Law Firm reminder and BusinessWire notice. Rosen Law Firm deadline notice Faruqi & Faruqi reminder

Institutional Trading of Ardent Health

Institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. lifted its stake in Ardent Health by 24.4% during the 4th quarter. Invesco Ltd. now owns 71,304 shares of the company’s stock valued at $630,000 after acquiring an additional 13,964 shares during the period. Empowered Funds LLC lifted its position in Ardent Health by 135.0% during the fourth quarter. Empowered Funds LLC now owns 551,738 shares of the company’s stock valued at $4,872,000 after purchasing an additional 316,961 shares during the period. VARCOV Co. purchased a new stake in Ardent Health in the fourth quarter worth approximately $232,000. Susquehanna Portfolio Strategies LLC raised its stake in Ardent Health by 101.8% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 62,957 shares of the company’s stock valued at $556,000 after buying an additional 31,758 shares during the last quarter. Finally, Numerai GP LLC purchased a new stake in Ardent Health during the 4th quarter valued at $616,000.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Guggenheim decreased their target price on Ardent Health from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Mizuho lowered their target price on shares of Ardent Health from $20.00 to $12.00 and set an “outperform” rating on the stock in a research note on Thursday, December 18th. KeyCorp downgraded Ardent Health from an “overweight” rating to a “sector weight” rating in a research report on Monday, November 17th. Truist Financial cut their price target on shares of Ardent Health from $21.00 to $13.00 and set a “buy” rating for the company in a research report on Friday, November 14th. Finally, UBS Group cut their target price on shares of Ardent Health from $14.50 to $14.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $14.58.

About Ardent Health

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.